CoChat

Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?

Open access
Takahashi, Saki, Greenhouse, Bryan, Rodríguez-Barraquer, Isabel · 2020 · The Journal of Infectious Diseases
Cited by 80

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Biased seroprevalence estimates can occur using serological assays optimized with validation sets unrepresentative of disease spectrum in the general population. Correct interpretation of serosurveys for severe acute respiratory syndrome coronavirus 2 requires quantifying variations in sensitivity with disease severity and over time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jiaa523

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 12

  1. Stringhini, 2020, Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland, Lancet, 396, P313, 10.1016/S0140-6736(20)31304-0 · DOI · Paper page
  2. US Food and Drug Administration, 2020, EUA authorized serology test performance
  3. Krammer, 2020, Serology assays to manage COVID-19., 1060
  4. Whitman, 2020, Test performance evaluation of SARS-CoV-2 serological assays, medRxiv [Preprint]
  5. Cervia, 2020, Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19, bioRxiv [Preprint]
  6. Solbach, 2020, Antibody profiling of COVID-19 patients in an urban low-incidence region in Northern Germany, medRxiv [Preprint]
  7. Bartolini, 2020, Immunochromatographic assays for COVID-19 epidemiological screening: our experience, medRxiv
  8. Lynch, 2020, Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity, Clin Infect Dis, 10.1093/cid/ciaa979 · DOI · Paper page
  9. Lei, 2020, Antibody dynamics to SARS-CoV-2 in asymptomatic and mild COVID-19 patients, medRxiv
  10. Sethuraman, Interpreting diagnostic tests for SARS-CoV-2, JAMA
  11. Iyer, 2020, Dynamics and significance of the antibody response to SARS-CoV-2 infection, medRxiv
  12. Diggle, 2011, Estimating prevalence using an imperfect test, Epidemiol Res Int, 1, 10.1155/2011/608719 · DOI · Paper page

Cited by

See all 80

Metadata

Authors
Takahashi, S., Greenhouse, B., & Rodríguez-Barraquer, I.
Venue
The Journal of Infectious Diseases
Published
2020-08-28
Volume
222
Issue
11
Pages
1772-1775
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W3080346431
Cited by
80
References
4
FWCI
1.99
Type
journal article
Language
en
Open access
bronze
Funders
Rhodes Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased? https://app.cochat.ai/papers/10.1093/infdis/jiaa523
The paper
Takahashi, S., Greenhouse, B., & Rodríguez-Barraquer, I. (2020). Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased? The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaa523

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.